Combination of an acetyl-CoA carboxylase inhibitor and fibroblast growth factor 19 reduced tissue triglyceride content and fibrosis in human precision-cut liver slices

被引：0
|
作者：
Tsai, Wen-Wei [1 ]
Borthwick, Lee [2 ]
Mann, Jelena [2 ]
Bates, Jamie [1 ]
Trevaskis, James L. [1 ]
机构：
[1] Gilead Sci, Foster City, CA USA
[2] FibroFind LTD, Gateshead, England
来源：
JOURNAL OF HEPATOLOGY | 2021年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PO-838
引用
收藏
页码：S614 / S614
页数：1
相关论文
共 4 条
  • [1] COMBINATION OF AN ACETYL-CoA CARBOXYLASE (ACC) INHIBITOR AND FIBROBLAST GROWTH FACTOR 19 (FGF19) REDUCED TISSUE TRIGLYCERIDE CONTENT AND FIBROSIS IN A 3D HUMAN LIVER MICROTISSUE MODEL OF NONALCOHOLIC STEATOHEPATITIS (NASH)
    Tsai, Wen-Wei
    Bieri, Manuela
    Grepper, Sue
    Thoma, Eva
    Trevaskis, James L.
    HEPATOLOGY, 2021, 74 : 1133A - 1133A
  • [2] A combination of fenofibrate with a liver-targeted acetyl-CoA carboxylase inhibitor enhances efficacy while reversing plasma triglyceride increases in a murine model of NASH
    Bates, Jamie
    Vijayakumar, Archana
    Hollenback, David
    Kusam, Saritha
    Burri, Harini
    Breckenridge, David G.
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E520 - E521
  • [3] Combination of an Acetyl-CoA carboxylase inhibitor and obeticholic acid reduced lipids and bile acids and altered lipid and amino acid metabolism in the liver of humanized mice
    Tsai, Wen-Wei
    Hollenback, David
    Schwab, Andrew
    Showalter, Megan
    Trevaskis, James
    JOURNAL OF HEPATOLOGY, 2022, 77 : S721 - S721
  • [4] Antifibrotic efficacy of a TGF-β kinase inhibitor on early-onset and end-stage of fibrosis in precision-cut human liver slices
    Luangmonkong, Theerut
    Suriguga, Suriguga
    Bigaeva, Emilia
    Oosterhuis, Dorenda
    de Jong, Koert P.
    Schuppan, Detlef
    Mutsaers, Henricus A.
    Olinga, Peter
    HEPATOLOGY, 2015, 62 : 909A - 910A
1